Asset Details
Do you wish to reserve the book?
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Do you wish to request the book?
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
2018
Overview
Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 T cells by cross-presenting exogenous antigens, plays a critical role in generating anti-tumor CD8 T cell immunity. However, there are compelling evidences now that the tumor microenvironment (TME)-mediated suppression and modulation of tumor-infiltrated DCs (TIDCs) impair their function in initiating potent anti-tumor immunity and even promote tumor progression. Thus, DC-mediated cross-presentation of tumor antigens in tumor-bearing hosts often induces T cell tolerance instead of immunity. As tumor-induced immunosuppression remains one of the major hurdles for cancer immunotherapy, understanding how DCs regulate anti-tumor CD8 T cell immunity in particular within TME has been under intensive investigation. Recent reports on the Batf3-dependent type 1 conventional DCs (cDC1s) in anti-tumor immunity have greatly advanced our understanding on the interplay of DCs and CD8 T cells in the TME, highlighted by the critical role of CD103
cDC1s in the cross-priming of tumor antigen-specific CD8 T cells. In this review, we will discuss recent advances in anti-tumor CD8 T cell cross-priming by CD103
cDC1s in TME, and share perspective on future directions including therapeutic applications and memory CD8 T cell responses.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antigens
/ Antigens, Neoplasm - immunology
/ Basic-Leucine Zipper Transcription Factors - metabolism
/ CD8-Positive T-Lymphocytes - immunology
/ Cell Communication - immunology
/ Dendritic Cells - immunology
/ Dendritic Cells - metabolism
/ Humans
/ Immunity
/ Melanoma
/ Repressor Proteins - metabolism
/ Tumor Microenvironment - immunology
/ Tumors
